ClinicalTrials.gov
public full text
Public Domain
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons. It is possible that when the amount of these germs is lowered, an HIV-infected person's immune system will become less active and will have a better chance of recovering. Also, the study will evaluate the safety of using rifaximin in HIV-infected subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct#1151797
- Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer#1164651
- Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients#864874
- A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802#872491
- Rifaximin in Patients With Diabetic Gastroparesis#878713
Record · ID 871104
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive